Drug Database
UR

urofollitropin (Follegon)

✓ Approved

Merck & Co. · FSHR

什么是 urofollitropin?

urofollitropin 是一种治疗药物,由Merck & Co.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。

药物档案

商品名Follegon
公司Merck & Co.
分子靶点FSHR
给药途径Injectable (Others)
状态Approved

作用机制

分子靶点

urofollitropin 作用于 1 个分子靶点:

FSHRfollicle stimulating hormone receptor (FSHRO, ODG1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

urofollitropin 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Reproductive system and breast disordersInfertility female✓ Approved

相关研究文献

PubMedHuman reproduction open2026-11-17

The management of endometriosis in adolescents and young adults: a systematic review.

Blyth Ursula U, Maslej Luba L, Bennett George G, Smith Carolyn C et al.

What evidence-based strategies are used in the treatment of endometriosis-associated symptoms in adolescents and young adults? The use of hormonal therapies and surgery was associated with improvements in pain symptoms in most studies; however, the certainty of evidence was very low, meaning that the true impact of these treatments remains uncertain. Endometriosis is a chronic condition estimated to affect 1 in 10 women, with symptoms commonly present during adolescence. Current management strategies for endometriosis include analgesia, hormonal suppression, and surgery, as well as non-pharmacological measures. This is a systematic review of the literature. Six databases (CINAHL, Cochrane Central Database of Controlled Trials, EMBASE, MEDLINE, PsychInfo, and Web of Science Core Collection) were searched from inception to May 2026. Search terms were related to endometriosis combined with terms regarding management and the adolescent age group. Eligible studies included participants aged under 24 years with endometriosis and reported on outcomes in the management of endometriosis-associated symptoms. Only studies with full texts or data available in English were included. Screening and data extraction were performed independently and in duplicate by two authors. Key outcomes included pain, quality of life, recurrence, and side effects. Data were reported narratively. Risk of bias was assessed according to study design (ROB2, NOS, and JBI tools) and quality of evidence with the GRADE system. The search identified 14 376 records, of which 333 full texts were assessed for eligibility, and 23 studies, with a combined total of 1561 participants, were included. There were two randomised controlled trials, one single-arm open-label interventional study, eleven cohort studies, and nine case series. Five studies investigated hormonal treatments, one other study assessed other pharmacological treatments, sixteen studies assessed surgical management with or without hormonal treatment, and one study investigated non-pharmacological treatments. Most studies reported improvements in pain symptoms; however, there was heterogeneity in study design, length of follow-up, and outcome measures. There is limited evidence in this age group. Most studies had a moderate risk of bias, and the certainty of evidence was very low. The very low certainty of evidence limits the ability to draw inferences from the data. More high-quality research is essential to understand the effectiveness of current treatments and identify how they should be tailored for this age group. No specific external or departmental funding was received for this systematic review. C.M.B. declares research grants from US DoD, NIH, EU Horizon 2020, Bayer AG, Aspira Ltd, Exeltis Ltd, Proteomics Inc, and Serac Healthcare Ltd, and consulting fees from Gedeon Richter, Theramex, Gesynta, and Roche (all paid to institution). C.M.B. is Chair of the ESHRE Endometriosis Guideline Group and a member of the NICE Endometriosis Guideline Group (unpaid). S.A.M. declares research grants (paid to institution) from AbbVie and the Marriot Family Foundations, received honoraria from the University of Kansas Medical Center and received travel support from LIDEA Registry, Taiwan Endometriosis Society, SEUD, Japan Endometriosis Society, NASEM, Endometriosis Foundation of America, Gedeon Richter, WES, New York Academy of Sciences, and Asian Conference on Endometriosis. S.A.M. is Field Chief Editor for Frontiers in Reproductive Health (personal fee) and is an advisory board member for the LIDEA Registry (personal fee) and has unpaid roles with Human Reproduction Statistical Advisory Board and the NextGen Jane Advisory Board, the Society for Women's Health Research, WERF, WES, ASRM, and ESHRE. K.V. reports research grants from the NIHR, NIH, UKRI, Medical Research Foundation, and EU IMI-2, consulting fees from Gesynta and Reckitts, and speakers' fees from Reckitts, Organon, Gedeon Richter, and Eli Lilly (all payments to institution). K.V. is a member of the Medical Advisory Panel of Endometriosis UK (unpaid). K.T.Z. declares research grants from the Gates Foundation, US DoD, NIH, EU Horizon 2020, Bayer AG, Aspira Ltd, Exeltis Ltd, Proteomics Inc, and Serac Healthcare Ltd and consulting fees from Apikal Ltd, Gedeon Richter, Roche, and LIDEA, (all paid to institution), and speaker's fees (paid to institution) from Rathlin Therapeutics and Camber Collective/Gates Foundation, received travel support for ESHRE 2025, SEUD 2024, EEC 2024, and LIDEA 2023, and is named on patent WO2024115891A1 relating to chronic pelvic pain treatment (NRG3), which is unrelated to the present manuscript. K.T.Z. is a board member of the World Endometriosis Foundation (unpaid). U.B., L.M., G.B., C.S., E.E., and P.M. declare no conflict of interest. Some of the above companies manufacture treatments discussed in this review. CRD420251018467.

PMID 43042315
阅读全文 →
PubMedAdvances in simulation (London, England)2026-11-01

Beyond knowledge gains - learner experience and technology acceptance of virtual reality for anatomy education in Zambia: a randomized exploratory study.

Barteit Sandra S, El Ahmadie Nizar N, Nieder Jessica J, Andreadis Petros P

Standalone virtual reality (VR) enables interactive exploration of three-dimensional anatomy, but comparative evidence from resource-constrained medical-education settings remains limited. This study explored immediate knowledge outcomes, learner acceptance, and experiences with VR and three other learning resources in Zambia. In this four-arm randomized exploratory study, 67 first- and second-year Bachelor of Science in Clinical Sciences students were assigned using Excel-generated random group numbers (1-4; no allocation concealment) to standalone VR using 3D Organon, AMBOSS®, curated textbook materials, or self-directed internet search for a self-paced learning session of up to 30 min. Knowledge was assessed using an unvalidated 10-item pre-post test, and immediate acceptance was measured with an adapted Technology Acceptance Model questionnaire. The primary between-group knowledge analysis used baseline-adjusted analysis of covariance with HC3-robust standard errors. Acceptance comparisons were adjusted for multiple testing. Brief open-text responses underwent qualitative content analysis. A pre-study review indicated that tested concepts could be located in the three fixed-content resources but did not establish equivalence in depth, organisation, or accessibility, and could not be applied to the self-directed internet group. The knowledge analysis included 59 participants (VR n = 12; AMBOSS® n = 17; textbook n = 16; Internet n = 14). Within-group increases reached the adjusted significance threshold in the AMBOSS®, textbook, and web-resource groups but not in the VR group (adjusted p = .053). The primary analysis did not detect an overall difference in baseline-adjusted post-test scores between modalities, F(3,54) = 1.945, p = .133; none of the six pairwise comparisons was significant after Holm adjustment. This finding does not establish equivalence. Acceptance analyses included 55-60 participants per construct. After adjustment across six domains, only Attitude differed significantly between modalities, H(3) = 11.801, ε² = 0.17, adjusted p = .049; AMBOSS® was rated more favourably than the self-directed internet search (adjusted p = .019, Cliff's δ = -0.60). Perceived ease of use and perceived enjoyment showed low internal consistency, limiting their interpretation. The qualitative corpus comprised 211 comments from 64 participants. Some VR participants valued visualisation, novelty, and enjoyment but reported navigation and content-access difficulties. AMBOSS® participants frequently valued organisation and accessibility, while experiences with textbook and web resources were mixed. This small exploratory study did not provide conclusive evidence of differences in immediate knowledge outcomes between the four modalities. Quantitative acceptance differences were also limited after adjustment for multiple comparisons. The findings identify content accessibility, curricular alignment, interface familiarization, and exposure time as priorities for larger, prospectively designed studies using validated instruments and longer-term outcomes.

PMID 42966864
阅读全文 →
PubMedHuman reproduction (Oxford, England)2026-10-09

Ovarian reserve after chemotherapy in premenopausal women with breast cancer undergoing fertility preservation counselling with and without unilateral ovarian tissue cryopreservation.

Yde Anna Mathilde AM, Colmorn Lotte Berdiin LB, Pinborg Anja A, Forman Julie Lyng JL et al.

What is the impact of chemotherapy on the ovarian reserve in premenopausal women diagnosed with breast cancer, and how is this impacted by fertility preservation (FP) strategy and age at diagnosis? Chemotherapy reduces ovarian reserve in women with breast cancer, with the greatest reductions observed among women who underwent ovarian tissue cryopreservation (OTC) and those of advanced reproductive age (≥35 years). Breast cancer is the most prevalent cancer among women of reproductive age, and in recent decades increasing emphasis has been placed on FP, including ovarian tissue, embryo, and oocyte cryopreservation. However, few large prospective studies have evaluated the effect of chemotherapy on ovarian reserve in patients with breast cancer using both anti-Müllerian hormone (AMH) and antral follicle count (AFC), and no large studies have assessed the impact by choice of FP. In this combined retro and prospective cohort study, we included 152 premenopausal women diagnosed with breast cancer who received FP counselling at Rigshospitalet, Copenhagen University Hospital, between 1 January 2018 and 31 August 2023. Women aged 18-42 years scheduled for FP counselling before chemotherapy were included. Exclusion criteria were previous chemotherapy, oophorectomy, and death or emigration within 2 years of inclusion. Medical and gynecological history, and oncological treatment plans were recorded. Ovarian reserve was assessed using AMH and AFC at baseline and at 6, 12, and 24 months after chemotherapy. Changes over time were analyzed using linear mixed models adjusted for age at baseline and hormonal contraceptive use. Of 152 women, 57 underwent OTC, while 41 underwent oocyte/embryo cryopreservation and 54 had no FP. Baseline median AMH was 13.9 [95% CI: 10.7, 18.1] pmol/l among women who did not undergo OTC and 13.3 [10.9, 16.3] pmol/l among those who did. A marked reduction in both AMH and AFC was observed after chemotherapy, with partial recovery within 2 years after treatment. The reduction was more pronounced, and recovery more limited, in women with OTC and in those of advanced reproductive age (≥35 years). Compared to baseline, the adjusted reduction in median AMH was 90% [95% CI: 85%, 93%] at 6 months and 75% [95% CI: 63%, 83%] at 24 months in women without OTC and 93% [95% CI: 85%, 95%] and 85% [95% CI: 78%, 90%] in women with OTC, respectively. Similar patterns, however, not as profound, were seen for AFC. Not all women completed assessments at all three follow-up visits, likely reflecting emotional exhaustion, hospital fatigue, reluctance to attend additional appointments, or changes in reproductive intentions. Furthermore, the observed reduction in ovarian reserve may, to some extent, also reflect the natural age-related decline in ovarian reserve. These findings may support counselling women with breast cancer about chemotherapy-related ovarian damage and thus the need for FP. The study is funded by the Independent Research Fund Denmark (Grant ID 10.46540/4308-00130B). A.P. has received grants (paid to the institution) and consulting fees from Gedeon Richter, Ferring Pharmaceuticals, Merck A/S, and Cryos; honoraria from Gedeon Richter, Ferring Pharmaceuticals, Merck A/S, and Organon; and support for meeting attendance and/or travel (paid to the institution) from Gedeon Richter. A.T.P. received speaker fees from Astellas, Gedeon-Richter, and Novo Nordisk. These companies had no role in the study. The other authors have no conflicts or interests to declare. N/A.

PMID 42853979
阅读全文 →
PubMedHuman reproduction (Oxford, England)2026-09-25

The two-shot protocol. A randomized controlled trial of a novel two-injection ovarian stimulation strategy.

Donno Valeria V, Sachs-Guedj Noemie N, Devesa Marta M, García-Martinez Sandra S et al.

Is the number of MII (metaphase II) oocytes comparable in the two-shot protocol versus the conventional corifollitropin alfa (CFA) followed by follitropin-beta protocol? Although the mean number of MII oocytes did not differ significantly between the two-shot protocol and the control group, non-inferiority was not statistically met. Controlled ovarian stimulation (COS) protocols are often associated with significant side effects, largely due to the burden of multiple daily injections. Efforts to develop more patient-friendly protocols include the shift from GnRH-agonist to antagonist protocols and the introduction of progestin protocol for pituitary suppression (PPS). While such patient-friendly approaches benefit infertile patients, they are even more appealing for women undergoing COS for elective fertility preservation. The current study aims to compare a novel ovarian stimulation protocol involving two sequential CFA injections (two-shot protocol) with a conventional approach using CFA and follitropin-beta in elective fertility preservation. Phase III, randomized, controlled, single-center, non-inferiority clinical trial conducted at a Fertility Unit within a University-Affiliated Hospital between December 2023 and July 2025. A total of 194 women were enrolled with a 1:1 allocation. Eligible participants were ≤40, with antral follicular count <20, and anti-Mullerian hormone (AMH) ≤ 3 ng/ml. Participants were randomized to receive either two sequential shots of CFA (150 mcg on Day 1 + 100 mcg on Day 5) or CFA (150 mcg) on Day 1, followed by recombinant FSH (200 IU/day) from Day 8. In both groups, the LH surge was suppressed using a PPS protocol with daily oral desogestrel 75 mcg from the beginning of stimulation until the trigger day. Final oocyte maturation was triggered with GnRH-agonist (triptorelin 0.2 mg). The primary outcome was to compare the two ovarian stimulation protocols in terms of the number of MII oocytes. Comparisons will be made using the estimated mean difference (MD) and corresponding 95% CI. A total of 194 patients were assessed for eligibility and randomized into two groups: 97 patients were assigned to the two-shot protocol (Group A), while 97 patients followed the conventional protocol involving CFA followed by rFSH (Group B). No statistically significant differences were found in the mean number of oocytes nor MII oocytes between the two-shot protocol and the control group, respectively, 8.09 ± 5.87 vs 9.11 ± 6.86; MD -1.02 [95% CI: -2.83; 0.79] and 6.14 ± 4.59 vs 7.19 ± 5.67, MD -1.04 [95% CI: -2.27; 0.18]. However, because the lower bound of the CI for the primary endpoint (-2.27) exceeded the pre-specified non-inferiority margin of -1.5 MII oocytes, non-inferiority of the two-shot protocol could not be demonstrated. Duration of stimulation (10.27 ± 1.69 vs 10.19 ± 1.47 days; MD 0.09 [95% CI -0.39; 0.56]) and number of follicles ≥14 mm on trigger day (10.67 ± 5.36 vs 11.14 ± 5.46; MD -0.47 [95% CI -2.11; 1.17]) were comparable between groups. The hormonal assessment performed during the stimulation revealed no clinically meaningful differences, except for the FSH concentrations, which were markedly higher in Group A on Day 8 (53.43 ± 13.28 vs 24.60 ± 8.33 IU/l; MD 28.82 [95% CI: 25.39; 32.25]) and remained higher on the day of ovulation trigger (31.28 ± 9.50 vs 24.46 ± 5.01 IU/l; MD 6.82 [95% CI: 4.32; 9.32]). The current study focused only in elective fertility preservation women, preventing conclusions on embryological differences between the protocols. Furthermore, since the sample size was powered to detect differences in the number of MII oocytes, findings for secondary outcomes, such as the hormonal profile, should be interpreted with caution. The two-shot protocol yielded a comparable number of MII oocytes to conventional stimulation; however, the pre-specified non-inferiority margin was not met, as the CI could not exclude a true reduction exceeding 1.5 MII oocytes. The point estimate of approximately one fewer MII oocyte is unlikely to be clinically meaningful, but larger studies are required before the protocol can be formally established as non-inferior. The study was supported by Fundación Santiago Dexeus Font and an unrestricted grant by Organon. N.P.P. has received research grant funding paid to the institution and personal honoraria for lectures from Organon. V.D. has received payment or honoraria for lectures from Organon. N.S.-G., M.D., S.G.-M., and I.R. have not conflict of interest to declare. NCT06134479. 18 November 2023. 18 December 2023.

PMID 42786378
阅读全文 →
PubMedNeurology. Education2026-09-06

Curriculum Innovation: Virtual Reality for Neuroanatomy Education Among Neurology Residents.

Gupta Ayush A, Bass Derek D, Barton Christopher R CR, Zhang Wanyu W et al.

Advanced neuroanatomy knowledge is essential for clinical reasoning in neurology, yet residency training offers limited time to reinforce concepts. This contributes to persistent gaps in topics frequently tested on the Residency In-service Training Examination (RITE). This study evaluated the feasibility and educational impact of a virtual reality (VR) neuroanatomy curriculum intended to enable residents to (1) identify and spatially integrate arterial, venous, and ventricular structures; (2) improve performance on assessments targeting commonly missed RITE concepts; and (3) assess usability, engagement, spatial presence, and perceived educational value. (1) To identify and label key neuroanatomical structures, (2) to describe spatial relationships relevant to clinical localization, (3) to apply neuroanatomy to clinical scenarios modeled after RITE items, and (4) to evaluate usability, engagement, and spatial presence of VR. A single-group, pre-post mixed-methods study among neurology residents at a single academic medical center. Participants completed a faculty-guided 40-minute VR session using Organon VR Anatomy on Meta Quest 3 headsets, focusing on cerebrovascular arterial supply, venous sinuses, ventricular anatomy, and key spatial relationships relevant to clinical localization. Knowledge was assessed using quizzes at baseline, postintervention, and at 2-week follow-up. Learner perceptions were measured using surveys, and data were analyzed using repeated-measures ANOVA and linear mixed-effects models, with mean differences and 95% confidence intervals reported. Thirty residents (mean age 30.5 years, SD 4.6; 50% female) completed all assessments. Mean scores increased from 8.57 (SD 2.75) at baseline to 11.37 (SD 2.27) immediately postintervention and were sustained at 11.20 (SD 3.07) at 2 weeks. The mean increase was 2.80 points (95% CI 1.45-4.15), representing an approximate 33% improvement, with sustained gains at follow-up (2.63 points; 95% CI 1.28-3.99). Participants reported high usability, engagement, and spatial presence. This study demonstrates the feasibility of an instructor-guided VR neuroanatomy curriculum and provides preliminary evidence of improved knowledge and short-term retention. Findings should be interpreted in the context of a single-group design and nonidentical assessments, which limit causal inference. VR seems to be a promising adjunct to traditional instruction, particularly when combined with guided teaching. Future controlled studies are needed to evaluate comparative effectiveness and long-term clinical impact.

PMID 42699696
阅读全文 →
PubMedThe European journal of contraception & reproductive health care : the official journal of the European Society of Contraception2026-08-17

Pharmacokinetic bioequivalence between (etonogestrel/ethinylestradiol 11.7/2.7 mg) NuvaRing® and Ornibel Premium® (etonogestrel/ethinylestradiol 8.25/2.6 mg), a novel polymer composition contraceptive vaginal ring.

Pérez de la Cruz María Ángeles MÁ, Diez Carlos C, Urek Sandra S, Matilla Sonia S et al.

This was a single-centre, randomised, single-ring insertion, 2-period, 2-sequence, crossover study designed to assess comparative bioavailability and thereby establish bioequivalence of two ethinylestradiol/etonogestrel vaginal rings (delivering 0.015/0.12 mg per day) after a single vaginal ring was inserted and worn for 28 days in healthy female subjects. Forty subjects were randomised for this bioequivalence study. The test product contains etonogestrel/ethinylestradiol 8.25/2.6 mg, compared with etonogestrel/ethinylestradiol 11.00/3.474 mg in the existing Ornibel® formulation, and was compared with NuvaRing (etonogestrel/ethinylestradiol 11.7/2.7 mg) as the reference product. The criteria for bioequivalence between the test and reference products were met. The test-to-reference ratio of geometric LSmeans and corresponding 90% CI for Cmax after Day 1, C504, AUC0-504, C672 and AUC0-672 were all within the acceptance range of 80.00 to 125.00% for ethinylestradiol and etonogestrel. The percentage reduction in residual hormone content remaining in the device after 21 days use, in comparison with NuvaRing®, is as follows: ETO residue after 21 days was reduced by 30%, and EE residue after 21 days was reduced by 4%. The test formulation (ethinylestradiol/etonogestrel vaginal ring delivering 0.015/0.12 mg per day; manufactured by Laboratorios Leon Farma, S.A.) is bioequivalent to the reference formulation (NuvaRing®; manufactured by N.V. Organon) following a single vaginal ring insertion worn for 28 days in healthy adult female subjects. Overall, the products tested were generally safe and well tolerated.

PMID 42605869
阅读全文 →

注册免费账户还可查看另外 1012 篇文献

免费注册查看全部文献 →

了解更多urofollitropin